{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:08:38Z","timestamp":1792008518683,"version":"4.4.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health grants","doi-asserted-by":"crossref","award":["F31DA043921"],"award-info":[{"award-number":["F31DA043921"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health grants","doi-asserted-by":"crossref","award":["UH3DA041146"],"award-info":[{"award-number":["UH3DA041146"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health grants","doi-asserted-by":"crossref","award":["P30DA033934"],"award-info":[{"award-number":["P30DA033934"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health grants","doi-asserted-by":"crossref","award":["F32DA047026"],"award-info":[{"award-number":["F32DA047026"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health grants","doi-asserted-by":"crossref","award":["T32DA007027"],"award-info":[{"award-number":["T32DA007027"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.drugalcdep.2019.06.006","type":"journal-article","created":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T10:38:13Z","timestamp":1566643093000},"page":"107501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone"],"prefix":"10.1016","volume":"204","author":[{"given":"Kathryn L.","family":"Schwienteck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Blake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T.","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin L.","family":"Poklis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Andrew","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Stevens","family":"Negus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1124\/jpet.109.152462","article-title":"Increased locomotor activity induced by heroin in mice: pharmacokinetic demonstration of heroin acting as a prodrug for the mediator 6-Monoacetylmorphine in vivo","volume":"331","author":"Andersen","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0010","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1016\/j.vaccine.2006.01.047","article-title":"A novel bivalent morphine\/heroin vaccine that prevents relapse to heroin addiction in rodents","volume":"24","author":"Anton","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41386-018-0197-3","article-title":"Vaccines to treat opioid use disorders and to reduce opioid overdoses","volume":"44","author":"Baehr","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0020","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.tips.2018.08.001","article-title":"Immunopharmacotherapies for treating opioid use disorder","volume":"39","author":"Banks","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0025","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1080\/00952990.2018.1458234","article-title":"Sex differences in opioid use and medical issues during buprenorphine\/naloxone treatment","volume":"44","author":"Barbosa-Leiker","year":"2018","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0030","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1124\/pr.115.011163","article-title":"Sex differences in animal models: focus on addiction","volume":"68","author":"Becker","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0035","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.drugalcdep.2011.10.018","article-title":"Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose\u2013effects and time-course","volume":"123","author":"Bigelow","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0040","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/252708a0","article-title":"Changes in heroin self-administration by a rhesus monkey after morphine immunisation","volume":"252","author":"Bonese","year":"1974","journal-title":"Nature"},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0045","doi-asserted-by":"crossref","first-page":"8601","DOI":"10.1021\/jacs.7b03334","article-title":"Development of a clinically viable heroin vaccine","volume":"139","author":"Bremer","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0050","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/mp400631w","article-title":"Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy","volume":"11","author":"Bremer","year":"2014","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.drugalcdep.2019.06.006_bib0055","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","article-title":"Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial","volume":"63","author":"Comer","year":"2006","journal-title":"Arch Gen Psych"},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0060","series-title":"Guide for the Care and Use of Laboratory Animals","year":"2011"},{"issue":"4","key":"10.1016\/j.drugalcdep.2019.06.006_bib0065","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.pbb.2008.02.006","article-title":"Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone","volume":"89","author":"Dean","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0070","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1017\/S1461145714000169","article-title":"Role of 6-monoacetylmorphine in the acute release of striatal dopamine induced by intravenous heroin","volume":"17","author":"Gott\u00e5s","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0075","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/bph.12305","article-title":"Levels of heroin and its metabolites in blood and brain extracellular fluid after iv heroin administration to freely moving rats","volume":"170","author":"Gott\u00e5s","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0080","first-page":"1","article-title":"Drug overdose deaths in the United States, 1999-2017","volume":"329","author":"Hedegaard","year":"2018","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0085","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jama.1991.03460080081037","article-title":"AN outbreak of designer drug\u2014related deaths in pennsylvania","volume":"265","author":"Hibbs","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0090","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/add.12573","article-title":"Efficacy of the nicotine vaccine 3\u2032\u2010AmNic\u2010rEPA (NicVAX) co\u2010administered with varenicline and counselling for smoking cessation: a randomized placebo\u2010controlled trial","volume":"109","author":"Hoogsteder","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0095","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1021\/acs.molpharmaceut.7b00933","article-title":"Enhancing efficacy and stability of an antiheroin vaccine: examination of Antinociception, opioid binding profile, and lethality","volume":"15","author":"Hwang","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0100","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1021\/acschemneuro.8b00079","article-title":"Efficacious vaccine against heroin contaminated with fentanyl","volume":"9","author":"Hwang","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0105","doi-asserted-by":"crossref","first-page":"11537","DOI":"10.1021\/acsomega.8b01478","article-title":"Improved admixture vaccine of fentanyl and heroin hapten immunoconjugates: antinociceptive evaluation of fentanyl-contaminated heroin","volume":"3","author":"Hwang","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0110","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1056\/NEJM198405103101902","article-title":"The pharmacokinetics of heroin in patients with chronic pain","volume":"310","author":"Inturrisi","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0115","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/0024-3205(83)90616-1","article-title":"Evidence from opiate binding studies that heroin acts through its metabolites","volume":"33","author":"Inturrisi","year":"1983","journal-title":"Life Sci."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0120","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0376-8716(03)00055-3","article-title":"From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States","volume":"70","author":"Jaffe","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0125","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1021\/acs.bioconjchem.5b00085","article-title":"Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers","volume":"26","author":"Jalah","year":"2015","journal-title":"Bioconj Chem"},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0130","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.drugalcdep.2018.12.026","article-title":"The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: a randomized trial","volume":"197","author":"Jarvis","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0135","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended\u2010release injectable naltrexone for opioid use disorder: a systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0145","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.vaccine.2014.01.028","article-title":"Facial recognition of heroin vaccine opiates: type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphine","volume":"32","author":"Matyas","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.drugalcdep.2019.06.006_bib0150","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13011-017-0137-y","article-title":"Patient perspectives of transitioning from prescription opioids to heroin and the role of route of administration","volume":"13","author":"Monico","year":"2018","journal-title":"Subst Abuse Treat Prevent Policy"},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0155","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.117.247049","article-title":"Opioid dose-and route-dependent efficacy of oxycodone and heroin vaccines in rats","volume":"365","author":"Raleigh","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0160","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.112.201194","article-title":"Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats","volume":"344","author":"Raleigh","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0165","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1742-7843.2006.pto_233.x","article-title":"Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients","volume":"98","author":"Rook","year":"2006","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0170","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1037\/pha0000183","article-title":"Naltrexone maintenance fails to alter amphetamine effects on intracranial self-stimulation in rats","volume":"26","author":"Sakloth","year":"2018","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0175","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2015.10345","article-title":"Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004-2013","volume":"314","author":"Saloner","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0180","series-title":"Key Substance Use and Mental Health Indicators in the United States: Results From the National Survey on Drug Use and Health (HHS Publication No. SMA 18-5068, NSDUH Series H-53)","author":"SAMHSA","year":"2018"},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0185","doi-asserted-by":"crossref","first-page":"9036","DOI":"10.1073\/pnas.1219159110","article-title":"Dynamic vaccine blocks relapse to compulsive intake of heroin","volume":"110","author":"Schlosburg","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0190","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.annemergmed.2014.07.017","article-title":"The potential threat of acetyl fentanyl: legal issues, contaminated heroin, and acetyl fentanyl \u201cdisguised\u201d as other opioids","volume":"64","author":"Stogner","year":"2014","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0195","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1021\/jm200461m","article-title":"A vaccine strategy that induces protective immunity against heroin","volume":"54","author":"Stowe","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0200","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1021\/acs.jmedchem.7b01427","article-title":"A stable heroin analogue that can serve as a vaccine Hapten to induce antibodies that block the effects of heroin and its metabolites in rodents and that cross-react immunologically with related drugs of abuse","volume":"61","author":"Sulima","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0205","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00213-006-0509-x","article-title":"Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin","volume":"189","author":"Sullivan","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1521-0391.2011.00186.x","article-title":"Compliance with buprenorphine medication\u2010assisted treatment and relapse to opioid use","volume":"21","author":"Tkacz","year":"2012","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0215","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1369-1600.2009.00161.x","article-title":"Route of administration affects the ability of naltrexone to reduce amphetamine\u2010potentiated brain stimulation reward in rats","volume":"14","author":"Todtenkopf","year":"2009","journal-title":"Addict. Biol."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0220","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/s41386-019-0385-9","article-title":"Conjugate vaccine produces long-lasting attenuation of fentanyl vs. Food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats","volume":"44","author":"Townsend","year":"2019","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0225","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-019-0356-1","article-title":"Sex differences in opioid reinforcement under a fentanyl vs. Food choice procedure in rats","author":"Townsend","year":"2019","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0230","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMsr1706626","article-title":"The role of science in addressing the opioid crisis","volume":"377","author":"Volkow","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0235","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.neulet.2013.08.033","article-title":"An industry perspective on the role and utility of animal models of pain in drug discovery","volume":"557","author":"Whiteside","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.drugalcdep.2019.06.006_bib0240","series-title":"Advances in Pharmacology","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/bs.apha.2015.12.002","article-title":"Chapter eleven - preclinical pharmacological approaches in drug Discovery for chronic pain","author":"Whiteside","year":"2016"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871619302601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871619302601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T06:23:09Z","timestamp":1574317389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871619302601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":48,"alternative-id":["S0376871619302601"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.06.006","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/577494","asserted-by":"object"}]},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107501"}}